Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Net Cash Flow (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Net Cash Flow for 3 consecutive years, with -$48.3 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 113.54% to -$48.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$293.2 million through Dec 2025, down 166.92% year-over-year, with the annual reading at -$293.2 million for FY2025, 166.92% down from the prior year.
  • Net Cash Flow hit -$48.3 million in Q4 2025 for NewAmsterdam Pharma, down from -$24.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $357.0 million in Q4 2024 to a low of -$193.4 million in Q2 2025.
  • Historically, Net Cash Flow has averaged $1.0 million across 3 years, with a median of -$28.3 million in 2023.
  • Biggest five-year swings in Net Cash Flow: soared 1179.15% in 2024 and later plummeted 290.43% in 2025.
  • Year by year, Net Cash Flow stood at -$33.1 million in 2023, then skyrocketed by 1179.15% to $357.0 million in 2024, then plummeted by 113.54% to -$48.3 million in 2025.
  • Business Quant data shows Net Cash Flow for NAMS at -$48.3 million in Q4 2025, -$24.4 million in Q3 2025, and -$193.4 million in Q2 2025.